TD Asset Management
KROS icon

TD Asset Management’s Keros Therapeutics KROS Stock Holding History

TD Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51,600
Closed -$817K – 1242
2024
Q4 		$817K Buy
+51,600
New +$2.68M ﹤0.01% 1136
2023
Q4 		– Sell
-36,200
Closed -$1.15M – 1420
2023
Q3 		$1.15M Buy
36,200
+18,100
+100% +$676K ﹤0.01% 1107
2023
Q2 		$727K Hold
18,100
– – ﹤0.01% 1194
2023
Q1 		$773K Buy
18,100
+8,100
+81% +$409K ﹤0.01% 1185
2022
Q4 		$480K Buy
+10,000
New +$467K ﹤0.01% 1293

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TD Asset Management's KROS Position: Q1 2025 in Review

TD Asset Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 51,600 shares — an estimated $817K sold.

TD Asset Management first reported a position in KROS in Q4 2022 and held it in 5 quarters. The position peaked at $1.15M in Q3 2023. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • TD Asset Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • TD Asset Management sold 51,600 Keros Therapeutics shares in Q1 2025, an estimated $817K.
  • TD Asset Management first reported a position in Keros Therapeutics in Q4 2022 and held it in 5 quarters.
  • TD Asset Management's Keros Therapeutics position peaked at $1.15M in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.